What Are HepaRG Cells and Why Are They Important?

HepaRG cells are a human liver cell line originally derived from a liver tumor in a patient with chronic hepatitis C, and they have become one of the most valued tools in liver research because they behave remarkably like actual human liver cells in ways that other lab-grown liver cells do not. Unlike the widely used HepG2 cell line, which has limited ability to metabolize drugs, HepaRG cells express the major drug-processing enzymes, transporters, and regulatory machinery found in freshly isolated human liver cells. That combination of accessibility and biological fidelity makes them useful across drug development, toxicology, disease modeling, and even experimental bioartificial liver devices.

Where HepaRG Cells Come From

The HepaRG cell line was established from a hepatocellular carcinoma associated with chronic hepatitis C infection.¹ That origin matters because it gave the cells an unusual property: they are bipotent, meaning they can develop into two distinct cell types. When cultured properly, HepaRG cells differentiate into both hepatocyte-like cells (the workhorses of liver metabolism) and biliary-like cells (which resemble the cells lining bile ducts).² This dual-lineage capacity sets HepaRG apart from virtually every other human hepatoma cell line, which tends to be locked into a single, often poorly differentiated state.

The practical upshot is that researchers get something closer to a miniature liver tissue than a flat sheet of identical tumor cells. In standard culture, proliferating HepaRG cells reach confluence and then begin sorting themselves into clusters of hepatocyte-like cells surrounded by biliary-like cells. If instead they are plated at low density, they pass through a progenitor stage before committing to one lineage or the other.² Researchers working on liver development and regeneration find this especially useful, because HepaRG cells let them study the transition from progenitor to mature liver cell in a reproducible human system.

How HepaRG Cells Mature in the Lab

Getting HepaRG cells to behave like functional liver cells requires a specific differentiation protocol, and the key ingredient is dimethyl sulfoxide, or DMSO. Adding about 2% DMSO to the culture medium drives the cells toward a mature hepatocyte-like state, boosting their expression of drug-metabolizing enzymes and liver-specific functions.³ The process typically involves growing the cells for about two weeks to reach confluence, then adding DMSO-containing medium for another two weeks or so. It is not a quick turnaround, but the result is a stable, well-differentiated cell population.

At the gene level, DMSO treatment drives the activation of genes controlled by nuclear receptors like PXR and PPARα, both of which play central roles in how the liver handles foreign chemicals.³ Other liver-specific genes, regulated by transcription factors like HNF1α and HNF4α, are expressed regardless of whether DMSO is present. The upshot is that the DMSO step does not create an artificial state so much as it coaxes the cells into completing a maturation program they are already wired for. Once differentiated, the cells maintain their metabolic capacity at relatively stable levels for several weeks, which gives researchers a comfortable working window.⁴

Drug-Metabolizing Enzymes and Transporters

The reason HepaRG cells have attracted so much attention is their metabolic profile. The human liver processes drugs primarily through a family of enzymes called cytochrome P450s, often abbreviated as CYPs. Differentiated HepaRG cells express the major CYP enzymes involved in drug metabolism, including CYP1A2, CYP2B6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4, at levels comparable to those found in cultured primary human hepatocytes.⁵ CYP3A4 alone handles about half of all marketed drugs, so having a cell line that expresses it robustly is a significant advantage.

Beyond the CYPs, HepaRG cells also express phase 2 conjugating enzymes (the downstream machinery that tags drug metabolites for excretion), along with the nuclear receptors that regulate the whole system, including the aryl hydrocarbon receptor, the pregnane X receptor (PXR), and the constitutive androstane receptor (CAR).⁵ When exposed to known enzyme inducers, the cells respond the way real liver cells do: CYP1A1, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A4 all ramp up at both the gene expression and enzyme activity levels.⁶

Drug transporters round out the picture. The liver moves drugs and their metabolites in and out of cells through specialized transporter proteins on both the blood-facing (sinusoidal) and bile-facing (canalicular) sides. HepaRG cells express functional transporters on both sides, including OCT1, OATPs, NTCP, MRPs, BSEP, and P-glycoprotein, and these transporters respond appropriately to known inducers like rifampicin and phenobarbital.⁷ Having both the metabolic enzymes and the transporters in one cell model means researchers can study the entire chain of events that happens when a drug enters a liver cell, gets metabolized, and gets shipped out.

Why They Beat HepG2 Cells

For decades, HepG2 cells were the default human liver cell line in research. They are easy to grow and widely available. The problem is that HepG2 cells have very low expression of the major CYP enzymes, respond weakly to chemical inducers, and lack many of the transporters found in real liver cells.⁸ In head-to-head comparisons, HepG2 cells showed only weak CYP activity after exposure to prototypical inducers, whereas HepaRG cells and primary human hepatocytes from multiple donors responded robustly at both the gene expression and enzyme activity levels.⁸

The transporter gap is just as stark. Differentiated HepaRG cells showed functional activity of OCT1, OATPs, OAT2, NTCP, MRPs, and P-glycoprotein, while HepG2 cells only showed meaningful MRP and P-glycoprotein activity.⁷ For any study that needs the cells to handle drugs the way a real liver does, HepG2 cells are simply not up to the task.

HepaRG cells also outperform other cell lines when it comes to predicting drug-induced liver injury. A comparative study tested HepaRG cells against L-02, HepG2, and human induced-hepatocyte-like cells (hiHeps) for their ability to flag drugs known to cause liver toxicity. HepaRG cells had the highest predictive accuracy, largely because their metabolic competence allowed them to generate the toxic metabolites that actually cause liver damage in patients.⁹

How They Compare to Primary Human Hepatocytes

Primary human hepatocytes, freshly isolated from donor livers, remain the gold standard for liver metabolism studies because they come directly from a real organ. But they have serious practical limitations. They are expensive, scarce, vary hugely from donor to donor, lose their metabolic functions rapidly once placed in culture, and cannot be expanded. HepaRG cells address most of these problems. They can be grown in large, reproducible batches from a single source, and their metabolic activity remains stable over weeks rather than days.

In direct comparisons, HepaRG cells show drug-metabolizing capacities that are comparable to, and in some cases higher than, those of primary human hepatocytes. One study found that CYP2C9, CYP2D6, and CYP3A4 activities were equal to or exceeded those measured in primary cells, and that albumin production and galactose elimination rates were higher in HepaRG cells.¹⁰ The consistency is the real selling point: running the same experiment on primary hepatocytes from three different donors can produce three different results, while HepaRG cells give the same baseline every time.

That said, HepaRG cells are not perfect replicas. They originate from a single individual’s tumor, so they reflect that person’s genetic background rather than the population as a whole. Some CYP enzymes are expressed at lower levels than the best primary hepatocyte preparations, and certain specialized liver functions (like urea production) have been found to be absent or very low in HepaRG cultures.¹⁰ Researchers tend to view HepaRG cells as a reliable first-pass model that can be supplemented with primary hepatocytes when donor-specific variability or full metabolic coverage matters.

Testing for Drug-Induced Liver Injury

Drug-induced liver injury is one of the leading reasons new drugs fail in clinical trials or get pulled from the market after approval. Identifying liver-toxic compounds early saves enormous time and money, and HepaRG cells have proven themselves useful at exactly this stage. In a multiparametric assay that measured cell viability, glutathione content, caspase activity, lipid accumulation, and albumin secretion, HepaRG cells achieved about 67% sensitivity and 73% specificity in detecting known liver-toxic drugs at high test concentrations.¹¹ At lower concentrations, specificity climbed to 87%, meaning relatively few safe drugs were falsely flagged as toxic.

The cells can also sustain different categories of chemical-induced liver damage, including steatosis (fatty liver), phospholipidosis (abnormal lipid buildup inside cells), and cholestasis (blocked bile flow), after both short-term and repeated exposure to reference drugs.⁴ The ability to model multiple types of liver injury in a single cell system is valuable because different drugs damage the liver through different mechanisms, and a model that only captures one type would miss the others. The comparative study mentioned earlier found that the key to HepaRG cells’ advantage over other lines in predicting liver injury was their sensitivity to oxidative stress, mitochondrial damage, and disordered lipid metabolism after exposure to toxic drugs.⁹

Modeling Fatty Liver Disease and Cholestasis

Beyond general toxicity screening, HepaRG cells have been adapted to study specific liver diseases. Fatty liver disease is a growing global health concern, and researchers have used HepaRG cells loaded with oleic acid to create an in vitro model of steatosis. When treated with various PPAR agonists (a class of drugs that influence fat metabolism), steatotic HepaRG cells showed reductions in fat droplets of up to 50%, driven by increased fatty acid burning and decreased fat production. The strongest effect came from a dual PPARα/γ agonist called muraglitazar, and the patterns matched what had been seen in clinical investigations.¹² This kind of concordance between cell-culture results and patient data is exactly what makes a model credible.

The same steatosis platform has been used to evaluate endocrine-disrupting chemicals suspected of contributing to metabolic disease. Researchers exposed HepaRG cells, with and without fatty acid supplementation, to ten compounds with known or suspected obesogenic properties, including bisphenol A, several PFAS compounds, and phthalates. The results showed that certain chemicals, particularly p,p’-DDE and DEHP, most effectively promoted fat droplet formation in the cells.¹³ Studies like this help clarify which environmental chemicals might contribute to fatty liver disease and through what pathways.

For cholestasis, HepaRG spheroids (three-dimensional clusters of cells) form bile canalicular structures, the tiny channels through which liver cells normally excrete bile. Researchers have used these structures to image bile acid transport and measure damage caused by drugs known to block bile flow.¹⁴ Having a human cell system that actually forms bile channels and moves bile acids through them is a meaningful step beyond flat-culture toxicity assays.

Three-Dimensional Culture and Organ-on-a-Chip Systems

Standard two-dimensional culture on a flat plastic dish does not capture the architecture of real liver tissue, and researchers have found that growing HepaRG cells in three-dimensional formats significantly improves their performance. In hanging-drop spheroid cultures, HepaRG cells showed markedly higher expression of CYP1A2, CYP2B6, and CYP3A4 compared to their 2D counterparts. The same 3D cultures also upregulated genes involved in gluconeogenesis, glycolysis, lipid synthesis, bile acid metabolism, and lipoprotein production.¹⁵ In other words, three-dimensional architecture pushes the cells toward a broader and more realistic portfolio of liver functions.

Microfluidic devices, sometimes called organ-on-a-chip platforms, take this further by introducing flow and spatial constraints that mimic the liver’s microscopic anatomy. In one such system, HepaRG cells formed cord-like structures three to four cells thick, resembling the plates of hepatocytes in an actual liver lobule. These structures had functional MRP2 transporters on the correct (apical) side and secreted albumin steadily for at least two weeks. Cells loaded as early-stage progenitors spontaneously differentiated into hepatocytes on the chip, while already-differentiated cells maintained their mature state.¹⁶ These miniaturized platforms open the door to studying how drugs behave in tissue-like environments rather than in flat cell layers.

Environmental Chemical Testing and CYP Induction

HepaRG cells are not limited to pharmaceutical testing. They are increasingly being used to study how environmental chemicals interact with liver metabolism. A recent study investigated whether six metabolism-disrupting chemicals (including bisphenol A, PFOA, and tributyltin) could induce CYP enzyme activity in HepaRG cells. Using a cocktail of CYP-selective probe substrates and mass spectrometry, researchers found that five of the six chemicals induced at least one CYP enzyme. PFOA was the most potent inducer of CYP2B6, while p,p’-DDE and bisphenol A were the strongest inducers of CYP3A4.¹⁷ The fact that the CYP induction test method had been previously validated for pharmaceuticals and was then adapted for environmental chemicals illustrates how HepaRG’s metabolic reliability lets researchers extend validated assays into new domains.

Genotoxicity and Regulatory Applications

One of the more consequential developments for HepaRG cells is their emergence in regulatory toxicology, specifically in genotoxicity testing. Standard genotoxicity assays often use cell lines that lack metabolic competence and require an external metabolic activation system (typically a rat liver extract called S9 mix) to generate reactive metabolites. This workaround introduces non-human metabolism, which can produce different metabolites than a human liver would. HepaRG cells sidestep this problem because they generate human-relevant metabolites on their own.

Studies evaluating HepaRG cells for the micronucleus assay, a standard test that detects chromosome damage, have found that they meet the acceptance criteria set by the OECD (Organisation for Economic Co-operation and Development), the international body that sets guidelines for chemical safety testing.¹⁸ A separate evaluation comparing HepaRG results with the regulatory-standard TK6 cell line across 28 diverse chemicals concluded that HepaRG cells should be incorporated into genotoxicity assessment frameworks as a more human-relevant approach.¹⁹

The potential regulatory payoff is significant. When a compound tests positive in the standard in vitro genotoxicity battery, the follow-up is usually a rodent study, which is expensive, time-consuming, and raises animal welfare concerns. If HepaRG-based assays can reliably determine whether a positive result is relevant to humans, they could reduce or replace some of that animal testing.¹⁸ This positions HepaRG cells at the center of the broader push toward “new approach methodologies,” or NAMs, in regulatory science.

Bioartificial Liver Devices

Perhaps the most ambitious application of HepaRG cells is in bioartificial liver systems, devices that aim to provide temporary liver support to patients in acute liver failure while they wait for a transplant or for their own liver to recover. The concept is straightforward: route the patient’s blood (or plasma) through a cartridge loaded with functional liver cells that detoxify it and return it. The challenge has always been finding a reliable, scalable cell source.

In an animal study, rats with acute liver failure treated with a bioartificial liver device loaded with HepaRG cells survived roughly 50% longer than those treated with an empty device. The HepaRG-loaded device also slowed the progression of brain swelling associated with liver failure, reduced kidney damage, and lowered ammonia levels in the blood.²⁰ A separate approach encapsulated HepaRG spheroids in alginate beads and found that by two weeks after encapsulation, the cells displayed albumin synthesis, ammonia and lactate detoxification, and CYP enzyme activity, a range of functions that maps onto what a patient in acute liver failure actually needs.²¹

These are still preclinical results, and bioartificial liver devices have a long history of promising lab data that has not yet translated into routine clinical use. But HepaRG cells solve one of the field’s persistent problems: they provide a reproducible, expandable human cell source with the metabolic competence needed to meaningfully process a patient’s blood. Primary human hepatocytes cannot be expanded to the quantities required, and other cell lines lack the enzymatic firepower. Whether this translates to clinical benefit in humans remains to be demonstrated, but the biological rationale is sound.